INTRODUCTION: In the last decade, substantial differences in the epidemiology of, antiretroviral therapy (ART) for, cascade of care in and support to people with HIV in vulnerable populations have been observed between countries in Western Europe, Central Europe (CE) and Eastern Europe (EE). The aim of this study was to use a survey to explore whether ART availability and therapies have evolved in CE and EE according to European guidelines. METHODS: The Euroguidelines in Central and Eastern Europe (ECEE) Network Group conducted two identical multicentre cross-sectional online surveys in 2019 and 2021 concerning the availability and use of antiretroviral drugs (boosted protease inhibitors [bPIs], integrase inhibitors [INSTIs] and nucleoside reverse transcriptase inhibitors [NRTIs]), the introduction of a rapid ART start strategy and the use of two-drug regimens (2DRs) for starting or switching ART. We also investigated barriers to the implementation of these strategies in each region. RESULTS: In total, 18 centres participated in the study: four from CE, six from EE and eight from Southeastern Europe (SEE). Between those 2 years, older PIs were less frequently used and darunavir-based regimens were the main PIs (83%); bictegravir-based and tenofovir alafenamide-based regimens were introduced in CE and SEE but not in EE. The COVID-19 pandemic did not significantly interrupt delivery of ART in most centres. Two-thirds of centres adopted a rapid ART start strategy, mainly in pregnant women and to improve linkage of care in vulnerable populations. The main obstacle to rapid ART start was that national guidelines in several countries from all three regions did not support such as strategy or required laboratory tests first; an INSTI/NRTI combination was the most commonly prescribed regimen (75%) and was exclusively prescribed in SEE. 2DRs are increasingly used for starting or switching ART (58%), and an INSTI/NRTI was the preferred regimen (75%) in all regions and exclusively prescribed in SEE, whereas the use of bPIs declined. Metabolic disorders and adverse drug reactions were the main reasons for starting a 2DR; in the second survey, HIV RNA <500 000 c/ml and high cluster of differentiation (CD)-4 count emerged as additional important reasons. CONCLUSIONS: In just 2 years and in spite of the emergence of the COVID-19 pandemic, significant achievements concerning ART availability and strategies have occurred in CE, EE and SEE that facilitate the harmonization of those strategies with the European AIDS Clinical Society guidelines. Few exceptions exist, especially in EE. Continuous effort is needed to overcome various obstacles (administrative, financial, national guideline restrictions) in some countries.

4th Department of Internal Medicine University General Hospital Attikon Medical School National and Kapodistrian University of Athens Athens Greece

Carol Davila University of Medicine and Pharmacy Victor Babes Clinical Hospital for Infectious and Tropical Diseases Bucharest Romania

Central Research Institute of Epidemiology Moskow Russia

City TB Hospital 2 St Petersburg Russia

Clinic for Infectious Diseases Clinical Center University of Sarajevo Sarajevo Bosnia and Herzegovina

Department for AIDS Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases Sofia Bulgaria

Department of Adults' Infectious Diseases Hospital for Infectious Diseases Medical University of Warsaw Warsaw Poland

Department of Infectious Diseases and Travel Medicine Charles University of Prague Prague Czech Republic

Department of Infectology and Geographical Medicine Academic L Derer's University Hospital Bratislava Slovakia

Department of Pharmacology Clinical Pharmacology and Toxicology School of Medicine University of Belgrade Belgrade Serbia

Ege University Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology Izmir Turkey

Gromashevsky Institute of Epidemiology and Infectious Diseases Viral Hepatitis and AIDS Department Kiev Ukraine

Infectious Diseases Clinic University Clinical Center at Kosovo Prishtina Kosovo

National Institute for Infectious Diseases Matei Bals Bucharest Romania

National Institute of Hematology and Infectious Diseases South Pest Central Hospital National Center of HIV Budapest Hungary

Republican Scientific and Practical Center for Medical Technologies Global Fund Grant Management Department Belarusian State Medical University Minsk Belarus

University Hospital for Infectious Diseases Zagreb Croatia

Vilnius University Faculty of Medicine Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

West Tallinn Central Hospital Tallinn Estonia

See more in PubMed

2021 UNAIDS Global AIDS Update-confronting inequalities-lessons for pandemic responses from 40 years of AIDS. Accessed 3 April 2022. https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update

Gourlay AJ, Pharris AM, Noori T, et al. Towards standardized definitions for monitoring the continuum of HIV care in Europe. AIDS. 2017;31(15):2053-2058. doi:10.1097/QAD.0000000000001597

UNAIDS. Understanding fast-track: accelerating action to end the AIDS epidemic by 2030. 2020. Accessed 8 August 2022. unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf

Gokengin D, Oprea C, Begovac J, et al. HIV care in central and Eastern Europe: how close are we to the target? Int J Infect Dis. 2018;70:121-130. doi:10.1016/J.IJID.2018.03.007

De Wit S, Battegay M, D'Arminio Monforte A, et al. European AIDS clinical society second standard of care meeting, Brussels 16-17 November 2016: a summary. HIV Med. 2018;19(2):77-80. doi:10.1111/HIV.12559

Brown AE, Hayes R, Noori T, et al. HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets. Euro Surveill. 2018;23(48):1. doi:10.2807/1560-7917.ES.2018.23.48.1800622

Kowalska JD, Oprea C, de Witt S, et al. Euroguidelines in central and Eastern Europe (ECEE) conference and the Warsaw declaration-a comprehensive meeting report. HIV Med. 2017;18(5):370-375. doi:10.1111/HIV.12436

Balayan T, Oprea C, Yurin O, et al. People who inject drugs remain hard-to-reach population across all HIV continuum stages in central, eastern and South Eastern Europe-data from euro-guidelines in central and Eastern Europe network. Infect Dis (Lond). 2019;51(4):277-286. doi:10.1080/23744235.2019.1565415

Miles to go-Global AIDS update 2018. Accessed 3 April 2022. https://www.unaids.org/en/20180718_GR2018

EACS guidelines. Accessed 3 April 2022. https://www.eacsociety.org/guidelines/eacs-guidelines/

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Accessed 3 April 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf; http://hivinfo.nih.gov

Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324(16):1651-1669. doi:10.1001/JAMA.2020.17025

Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, et al. HIV care in times of the COVID-19 crisis-where are we now in central and Eastern Europe? Int J Infect Dis. 2020;96:311-314. doi:10.1016/J.IJID.2020.05.013

World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Published 2017. Accessed 3 April 2022. https://www.who.int/publications/i/item/9789241550062

Boyd MA, Boffito M, Castagna A, Estrada V. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med. 2019;20(Suppl 1):3-11. doi:10.1111/HIV.12708

Michienzi SM, Barrios M, Badowski ME. Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV. Curr Infect Dis Rep. 2021;23(5):7. doi:10.1007/S11908-021-00750-5

Boucher CA, Bobkova MR, Geretti AM, et al. State of the art in HIV drug resistance: science and technology knowledge gap. AIDS Rev. 2018;20(1):27-42.

Waters L, Church H. Two drugs regimens for HIV. Curr Opin Infect Dis. 2020;33(1):28-33. doi:10.1097/QCO.0000000000000615

Badowski M, Pérez SE, Silva D, Lee A. Two's a company, Three's a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-Naïve and treatment-experienced patients living with HIV-1. Infect Dis Ther. 2020;9(2):185-208. doi:10.1007/S40121-020-00290-W

Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to Dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a Tenofovir Alafenamide-based 3- or 4-drug regimen for maintenance of Virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920-1929. doi:10.1093/CID/CIZ1243

Mbhele N, Chimukangara B, Gordon M. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343. doi:10.1016/J.IJANTIMICAG.2021.106343